Risk for haematological malignancies with glucagon‐like peptide‐1 receptor agonists and dual agonists: A meta‐analysis
- 30 October 2026
- journal article
- Published by Wiley in British Journal of Haematology
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Risk for Cancer With Glucagon-Like Peptide-1 Receptor Agonists and Dual AgonistsAnnals of Internal Medicine, 2026
- Hematologic Cancers Among Patients With Type 2 Diabetes Prescribed GLP-1 Receptor AgonistsJAMA Network Open, 2025
- Differential Effects of GLP-1 Receptor Agonists on Cancer Risk in Obesity: A Nationwide Analysis of 1.1 Million PatientsCancers, 2024
- Glucagon-like peptide 1 (GLP-1)Molecular Metabolism, 2019
- RoB 2: a revised tool for assessing risk of bias in randomised trialsBMJ, 2019
- The Peto odds ratio viewed as a new effect measureStatistics in Medicine, 2014
- A simple confidence interval for meta‐analysisStatistics in Medicine, 2002
- A refined method for the meta‐analysis of controlled clinical trials with binary outcomeStatistics in Medicine, 2001